Form 8-K Kite Pharma, Inc. For: Aug 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil up almost 2% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Standpoint Research Starts Kite Pharma (KITE) at Buy
August 17, 2015 9:42 AM EDTStandpoint Research initiated coverage on Kite Pharma (NASDAQ: KITE) with a Buy rating and a price target of $100.00.
For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.
Shares of Kite Pharma closed at $58.00 yesterday.
... More